GSK announces positive results from DREAMM-8 phase III trial for ...
Mar 7, 2024 · Blenrep (belantamab mafodotin) plus PomDex showed statistically significant and clinically meaningful progression-free survival compared to bortezomib plus PomDex; Consistent efficacy results observed for Blenrep combinations in two phase III head-to-head trials
GSK will pull Blenrep from US market after failed trial
2 days ago · GSK confirmed this morning that the disappointing readout from the DREAMM-3 trial of multiple myeloma therapy Blenrep reported earlier this month means that it will take the drug off the US...
After withdrawal, GSK touts another Blenrep combo win as …
Mar 7, 2024 · GSK has more trial evidence to support a potential comeback for its withdrawn antibody-drug conjugate Blenrep. In patients with previously treated multiple myeloma, Blenrep beat Takeda’s...
With trial win, GSK could get blood cancer drug back on market
Jun 2, 2024 · At the annual American Society of Clinical Oncology conference in Chicago, researchers on Sunday are presenting trial data showing that the drug, called Blenrep, …
FDA approves GSK’s BLENREP (belantamab mafodotin-blmf) for …
GlaxoSmithKline announced the US Food and Drug Administration (FDA) has approved BLENREP (belantamab mafodotin-blmf) as a monotherapy treatment for adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor and an immunomodulatory ...
DREAMM-7 phase III trial shows Blenrep combination nearly tripled ... - GSK
Feb 5, 2024 · GSK plc (LSE/NYSE: GSK) today announced results from an interim analysis of the DREAMM-7 phase III head-to-head trial evaluating Blenrep (belantamab mafodotin) combined with bortezomib plus dexamethasone (BorDex) versus daratumumab plus BorDex in second-line and later treatment of relapsed or refractory multiple myeloma.
GSK backs up its Blenrep rehab bid with survival data
Feb 7, 2024 · GSK has reported data it hopes will allow a return to the US for Blenrep, the first BCMA-targeting drug to launch for multiple myeloma.
GSK provides an update on Blenrep (belantamab mafodotin …
Nov 22, 2022 · GSK plc (LSE/NYSE: GSK) today announced it has initiated the process for withdrawal of the US marketing authorisation for Blenrep (belantamab mafodotin-blmf) following the request of the US Food and Drug Administration (FDA).
DREAMM-8 Phase III Trial for Blenrep | Int'l Myeloma Foundation
Mar 7, 2024 · GSK press releases reports on positive results from DREAMM-8 phase III trial for Blenrep versus standard of care combination in relapsed/refractory multiple myeloma.
Phase III Blenrep Trial | Int'l Myeloma Foundation
Nov 27, 2023 · The ongoing DREAMM-8 trial will evaluate belantamab mafodotin in combination with pomalidomide and dexamethasone versus bortezomib in combination with pomalidomide and dexamethasone, with data expected in the second half of 2024. Read the full press release to …